Risk of thromboembolism in patients with ALK‐ and EGFR‐mutant lung cancer: A cohort study

Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study

(2020) Stavros K. Kakkos et al.   INTERNATIONAL ANGIOLOGY

Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer

(2020) Hanny Al-Samkari et al.   Journal of Thoracic Oncology

Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients

(2020) Orly Leiva et al.   Cancers

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta‐analysis

(2019) Ang Li et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)

(2019) Mariano Provencio et al.   Translational Lung Cancer Research

Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study

(2019) Feifei Dou et al.   THROMBOSIS RESEARCH

The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism

(2019) Jing Wang et al.   Annals of Translational Medicine

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK -rearranged non-small cell lung cancer

(2018) Jon Zugazagoitia et al.   EUROPEAN RESPIRATORY JOURNAL

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

(2018) Benjamin J. Solomon et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future

(2018) Alok A. Khorana et al.   THROMBOSIS RESEARCH

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

(2018) D. Ross Camidge et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

(2018) Marc Carrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events

(2018) Terry L. Ng et al.   Journal of Thoracic Oncology

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial

(2017) Saroj Vadhan-Raj et al.   THROMBOSIS AND HAEMOSTASIS

Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma

(2017) Elsa Davidsson et al.   MULTIDISCIPLINARY RESPIRATORY MEDICINE

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

(2016) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma

(2015) Melina Verso et al.   THROMBOSIS RESEARCH

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer

(2014) Yun-Gyoo Lee et al.   THROMBOSIS AND HAEMOSTASIS

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

(2014) Puey Ling Chia et al.   Clinical Epidemiology

Prevalence and Clinical Significance of Incidental and Clinically Suspected Venous Thromboembolism in Lung Cancer Patients

(2013) Gregory C. Connolly et al.   Clinical Lung Cancer

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

(2012) Ji-lin Guan et al.   ANNALS OF SURGICAL ONCOLOGY

Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis

(2012) M. CARRIER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer

(2011) Peter M. Ellis et al.   Journal of Thoracic Oncology

Venous thromboembolism and nonsmall cell lung cancer

(2009) Lisa K. Hicks et al.   CANCER

Assessing Risk of Venous Thromboembolism in the Patient With Cancer

(2009) Alok A. Khorana et al.   JOURNAL OF CLINICAL ONCOLOGY